Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 10;12:678483. doi: 10.3389/fimmu.2021.678483

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Del Campo, Bouley, Chevandier, Rousset, Haller, Indalecio, Guyon-Gellin, Le Vert, Hill, Djebali, Leverrier, Marvel, Combadière and Nicolas

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

OVX836 activates CD8α+ DC and promotes effector T-cell responses in vitro. (A) Mean CD86 expression on purified CD8a⁺ DCs incubated for 18 h with 2 µg/ml NPm (36 nM NP), NPwt (36 nM NP), OVX836 (32 nM NP), or a positive control. (B) Graph shows the percentage of specific CD8+ T cells that were positive for IFNγ, measurement of IFNγ production by NP-specific CD8⁺ T-cells incubated for 6 h with antigen-loaded DCs (as indicated) at a 5:1 (DC/CD8) ratio, then analyzed by flow cytometry. CD8⁺ T-cells used in the assay were isolated from the spleen of mice immunized with 30 µg of NP_366–374 peptide in IFA. NP_366–374 was used as a positive control in the assay. Results are representative of two independent experiments.